ResearcherUniversity of Maryland, BaltimoreNo recent work listed
Xiang 'Anthony' Chen
Matched on ORCID iD 0000-0002-2499-8261; OpenAlex author ID A5100441917. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper
Papers 5
- Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go? Co-author DOI 10.3389/fonc.2022.828223↗
- High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.05.011↗
- Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. Co-author DOI 10.1097/md.0000000000026342↗
- Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Co-author DOI 10.2174/1568009618666180430123939↗
- Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells. First author DOI 10.3892/ijo.2018.4389↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jiayuh Lin · 2 shared papers, 2018–2019 · strength 0.26
- Paper Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human P… DOI 10.2174/1568009618666180430123939↗
- Paper Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic canc… DOI 10.3892/ijo.2018.4389↗
- Dan Chen · 2 shared papers, 2021–2022 · strength 0.25
- Chenqi Wang · 2 shared papers, 2021–2022 · strength 0.25
- Yunlong Chen · 2 shared papers, 2021–2022 · strength 0.25
- Jiangning Gu · 2 shared papers, 2021–2022 · strength 0.25
- Haifeng Luo · 2 shared papers, 2021–2022 · strength 0.25
- Gloria Huei-Ting Su · 1 shared paper, 2019 · strength 0.14
- Lili Yang · 1 shared paper, 2022 · strength 0.13
- Guang Tan · 1 shared paper, 2022 · strength 0.13
- Anthony Lin · 1 shared paper, 2021 · strength 0.12
- Yi‐Chieh Nancy Du · 1 shared paper, 2021 · strength 0.12
- Jian Du · 1 shared paper, 2021 · strength 0.12
- Shengling Fu · 1 shared paper, 2018 · strength 0.12
- Huey-Jen L. Lin · 1 shared paper, 2018 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.